Australia - English - Department of Health (Therapeutic Goods Administration)

nature's care manufacture pty limited - natural fish oil, quantity: 130 mg (equivalent: eicosapentaenoic acid, qty 23.4 mg; equivalent: docosahexaenoic acid, qty 15.6 mg); evening primrose oil, quantity: 25 mg (equivalent: gamma-linolenic acid, qty 2.5 mg); cod-liver oil, quantity: 100 mg (equivalent: vitamin a, qty 30 re; equivalent: colecalciferol, qty 10 iu); d-alpha-tocopherol, quantity: 5 mg; lecithin, quantity: 50 mg; squalene, quantity: 500 mg - capsule, soft - excipient ingredients: glycerol; gelatin; soya oil; purified water - helps enhance/promote general health and wellbeing ; maintain/support general health and wellbeing

Australia - English - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - influenza virus haemagglutinin, quantity: 15 microgram - injection, suspension - excipient ingredients: monobasic potassium phosphate; magnesium chloride hexahydrate; sorbitan trioleate; squalene; sodium citrate dihydrate; citric acid monohydrate; calcium chloride dihydrate; potassium chloride; water for injections; sodium chloride; dibasic sodium phosphate dihydrate; polysorbate 80 - active immunisation against influenza in persons 65 years of age and older.

Australia - English - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - influenza virus haemagglutinin, quantity: 15 microgram - injection, suspension - excipient ingredients: monobasic potassium phosphate; magnesium chloride hexahydrate; sorbitan trioleate; squalene; sodium citrate dihydrate; citric acid monohydrate; calcium chloride dihydrate; potassium chloride; water for injections; sodium chloride; dibasic sodium phosphate dihydrate; polysorbate 80 - active immunisation against influenza in persons 65 years of age and older.

Australia - English - Department of Health (Therapeutic Goods Administration)

bridgewest perth pharma pty ltd - atropine sulfate monohydrate, quantity: 600 microgram/ml - injection, solution - excipient ingredients: water for injections; sodium chloride - indications as at 23 october 2001: preanaesthetic medication to reduce salivary secretions and bronchial secretions. to prevent cholinergic cardiac effects such as cardiac arrhythmias, hypotension and bradycardia. management of patients with acute myocardial infarction and sinus bradycardia who have associated hypotension and increased ventricular irritability. concurrent administration with anticholinesterase agents (eg. neostigmine, physostigmine) to block the adverse muscarinic effects of these agents following surgery to terminate curarisation. for poisoning by organophosphate pesticides, atropine may be used concomitantly with a cholinesterase reactivator such as pralidoxime to reverse muscarinic effects.

Australia - English - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - influenza virus haemagglutinin, quantity: 30 microgram/ml - injection, suspension - excipient ingredients: sodium chloride; potassium chloride; monobasic potassium phosphate; dibasic sodium phosphate dihydrate; magnesium chloride hexahydrate; calcium chloride dihydrate; squalene; polysorbate 80; sorbitan trioleate; sodium citrate dihydrate; citric acid monohydrate; water for injections - active immunisation against influenza in the elderly (65 years of age and older), especially for those with an increased risk of associated complications (i.e. patients affected by underlying chronic diseases including diabetes, cardiovascular and respiratory diseases).

Australia - English - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - influenza virus haemagglutinin, quantity: 30 microgram/ml - injection, suspension - excipient ingredients: sodium chloride; potassium chloride; monobasic potassium phosphate; dibasic sodium phosphate dihydrate; magnesium chloride hexahydrate; calcium chloride dihydrate; squalene; polysorbate 80; sorbitan trioleate; sodium citrate dihydrate; citric acid monohydrate; water for injections - active immunisation against influenza in the elderly (65 years of age and older), especially for those with an increased risk of associated complications (i.e. patients affected by underlying chronic diseases including diabetes, cardiovascular and respiratory diseases).

Australia - English - Department of Health (Therapeutic Goods Administration)

greensvich pty ltd - squalene -

Australia - English - Department of Health (Therapeutic Goods Administration)

tasman pacific holding pty ltd - squalene -

Australia - English - Department of Health (Therapeutic Goods Administration)

good health products australia - squalene, quantity: 1000 mg - capsule, soft - excipient ingredients: purified water; gelatin; glycerol; d-alpha-tocopherol - antioxidant/reduce free radicals formed in the body ; helps reduce/decrease free radical damage to body cells ; helps enhance/promote general health and wellbeing ; maintain/support general health and wellbeing

Australia - English - Department of Health (Therapeutic Goods Administration)

sini australia pty ltd - squalene, quantity: 1000 mg - capsule, soft - excipient ingredients: gelatin; glycerol; purified water - antioxidant/reduce free radicals formed in the body ; maintain/support general health and wellbeing ; maintain/support healthy immune system function ; maintain/support skin health